טוען...
Expectations of Serious Adverse Events at the End-of-Life of Patients with Acute Myeloid Leukemia Who Receive Salvage Therapy
BACKGROUND: Patients with acute myeloid leukemia (AML) and refractory disease receive investigational therapies within 2 months of their death. The attribution of serious adverse events (AE) in this phase to disease progression versus drug toxicity is tenuous. We aimed to determine the incidences of...
שמור ב:
| הוצא לאור ב: | Clin Lymphoma Myeloma Leuk |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2013
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4341913/ https://ncbi.nlm.nih.gov/pubmed/23763918 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2013.03.021 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|